United Bank Invests $1.26 Million in Zimmer Biomet Holdings, Inc. $ZBH

United Bank purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,621 shares of the medical equipment provider's stock, valued at approximately $1,259,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Brighton Jones LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter valued at $232,000. Federated Hermes Inc. boosted its position in Zimmer Biomet by 129.2% during the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider's stock worth $194,000 after purchasing an additional 1,202 shares during the period. Cerity Partners LLC boosted its position in Zimmer Biomet by 93.6% during the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider's stock worth $7,004,000 after purchasing an additional 37,116 shares during the period. Finally, Daiwa Securities Group Inc. increased its holdings in Zimmer Biomet by 5.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 29,889 shares of the medical equipment provider's stock valued at $2,726,000 after purchasing an additional 1,511 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $100.65 on Thursday. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a market capitalization of $19.20 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.70 and a beta of 0.45. The company's fifty day moving average price is $92.16 and its two-hundred day moving average price is $90.85.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the firm earned $2.07 earnings per share. The company's revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Wall Street Analyst Weigh In

Several research firms have commented on ZBH. BMO Capital Markets reissued a "market perform" rating and issued a $96.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Sanford C. Bernstein increased their target price on Zimmer Biomet from $91.00 to $93.00 and gave the company a "market perform" rating in a research note on Thursday, August 6th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Truist Financial boosted their price target on Zimmer Biomet from $92.00 to $106.00 and gave the stock a "hold" rating in a research report on Thursday, August 6th. Finally, Citizens Jmp decreased their price target on Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating for the company in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $104.42.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.28% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source